 Shares of Luminex NASDAQ:LMNX moved higher by 6.77 in after-market trading after the company reported Q2 results.Quarterly Results Earnings per share rose 370.00 year over year to 0.27, which beat the estimate of 0.08.Revenue of 109,519,000 rose by 31.86 year over year, which beat the estimate of 107,330,000.Looking Ahead Earnings guidance hasnt been issued by the company for now.Luminex hasnt issued any revenue guidance for the time being.Conference Call Details Date: Aug 04, 2020View more earnings on LMNXTime: 05:00 PMET Webcast URL: Stock Performance 52-week high: 40.2152-week low: 17.34Price action over last quarter: Up 6.86Company Profile Luminex Corp is a United States based company that develops, manufactures and sells proprietary biological testing technologies and products with applications throughout the life sciences industries, including diagnostics, pharmaceutical, and research. Its products include MAGPIX, Luminex 100200, and FLEXMAP 3D. Their key market segments are molecular infectious disease, genetic or inherited disease, human leukocyte antigen HLA transplant diagnostics, immunodiagnostics, and life sciences research. It offers various solutions in diverse markets including clinical diagnostics, pharmaceutical drug discovery, biomedical research, genomic and proteomic research, and food safety.See more from Benzinga Axcelis Technologies: Q2 Earnings Insights Recap: Ethan Allen Interiors Q4 Earnings Twilio: Q2 Earnings InsightsC 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. 